Tag - IDIA

Idorsia (SIX: IDIA) has announced positive top-line results from its Phase 2 dose-finding study evaluating 10, 25, and 50 mg doses of daridorexant—the company’s dual orexin receptor antagonist (DORA)—in pediatric...